Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:19 - Any
Updated:6/8/2018
Start Date:April 5, 2018
End Date:December 2020
Contact:Vanderbilt-Ingram Service for Timely Access
Email:cip@vanderbilt.edu
Phone:800-811-8480

Use our guide to learn which trials are right for you!

Predictors of Response to Immune Checkpoint Inhibitors in Non-small Cell and Small Cell Lung Cancer

This pilot clinical trial studies how well bronchoscopy with bronchoalveolar lavage works in
identifying biomarkers of response to immune checkpoint inhibitors in patients with non-small
cell or small cell lung cancer. Bronchoscopy uses a thin, tube-like instrument inserted
through the nose or mouth to view the inside of the trachea, air passages, and lungs.
Bronchoalveolar lavage washes out the bronchi and alveoli by flushing with a fluid.
Bronchoscopy with bronchoalveolar lavage may make it easier to help determine biomarkers that
are more present in some cancers than others that will help determine which individuals have
a greater or lesser chance of benefiting from immunotherapy.

PRIMARY OBJECTIVES:

I. To discover predictive immune biomarkers of response to immune checkpoint inhibitor
therapy in individuals with primary lung cancer.

SECONDARY OBJECTIVES:

I. To determine biomarkers that may be predictive of treatment related adverse events,
specifically pneumonitis.

II. To further elucidate lung immunologic microenvironment by performing single cell analysis
in addition to mass cytometry (Cytof) on cells of bronchoalveolar lavage.

OUTLINE:

Patients undergo bronchoscopy with bronchoalveolar lavage over 45 minutes.

After completion of study, patients are followed up at 3, 6, 12, and 24 months.

Inclusion Criteria:

- Confirmed diagnosis of non-small cell lung cancer (NSCLC) or small cell lung cancer
(SCLC)

- Candidate to undergo immune checkpoint inhibitor (ICI) therapy for SCLC or NSCLC (ICI
as any line of chemotherapy is acceptable) as deemed by individual's treating
oncologist

- Enrollment into this study may occur in tandem with other clinical therapeutics trials
occurring at Vanderbilt University Medical Center (VUMC) as long as this trial does
not violate protocol or inclusion criteria of that study

Exclusion Criteria:

- Coagulopathy with international normalized ratio (INR) > 2.0 or

- Coagulopathy with platelets (Plt) < 10 k

- Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4
antibody (including ipilimumab or any other antibody or drug specifically targeting
T-cell co-stimulation or checkpoint pathways)

- Subjects with an active or recent history of a known or suspected autoimmune disease
or recent history of a syndrome that required systemic
corticosteroids/immunosuppressive medications

- Respiratory failure requiring greater than 6 Lpm supplemental oxygen (O2) by nasal
cannula or mechanical ventilation within the past six weeks

- Inability to perform informed consent due to any medical or psychiatric condition
We found this trial at
1
site
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Principal Investigator: Fabien Maldonado, MD
Phone: 800-811-8480
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials